Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.
A nationwide French study reveals that nearly half of maternal deaths due to venous thromboembolism are preventable, emphasizing the importance of ongoing risk assessment and appropriate thromboprophylaxis during pregnancy and postpartum.
A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in re
Spatial remodeling of bone marrow in myelodysplastic neoplasms (MDS) reveals distinctive tissue-state signatures that better capture disease activity and predict therapeutic response beyond traditional blast counts.
This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating a
Mutant IDH1 in acute myeloid leukemia causes a reversible block in neutrophil differentiation by repressing myeloid progenitor transcriptional programs, highlighting a preleukemic defect with therapeutic implications.
A novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable sa
Blood or marrow transplant recipients face an increased risk of skin cancers. This study develops validated risk models to identify high-risk patients for basal cell carcinoma, squamous cell carcinoma, and melanoma to optimize surveillance
A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffectiv
The ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing acti
A comprehensive retrospective analysis of 793 adult allo-HSCT cases identifies key clinical risk factors and validates the EASIX score as a predictive biomarker for SOS/VOD, highlighting the syndrome’s significant impact on non-relaps
This review synthesizes evidence on combining lenalidomide and oral azacitidine with radiotherapy for plasmacytoma, highlighting safety, preliminary efficacy, and translational rationale in newly diagnosed and relapsed patients.
USP8 regulates proteostasis in B cells and multiple myeloma, influencing cellular survival and response to therapy. Targeting USP8 reveals new opportunities for overcoming proteasome inhibitor resistance in multiple myeloma.
This review synthesizes evidence revealing l-carnitine’s pivotal role in human hematopoietic stem and progenitor cell regeneration via fatty acid oxidation, highlighting metabolic profiling advances and translational potential for reg
This multicenter study identifies peripheral blood stem cell use as a key risk factor for early inflammatory complications post-haploidentical HSCT in children, linking these events to refractory acute and chronic graft-versus-host disease.
This study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibito
Excess folic acid promotes erythropoiesis impairment in myelodysplastic neoplasms via the FOLR2-IRF2BP2 axis, revealing potential therapeutic targets involving dietary folic acid restriction and pathway inhibition.
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
This study evaluates survival and relapse outcomes of total body irradiation versus chemotherapy conditioning regimens in haploidentical hematopoietic cell transplantation for adult AML patients in first remission, revealing no clear surviv
The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome
Open language-specific specialty feeds and department pages.